Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient FDA Decision: AMAG Pharmaceuticals (AMAG)

The Phase 3 date for Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient by AMAG Pharmaceuticals (AMAG) is scheduled for November 1, 2025. This is the target date for the FDA to make a decision on this application.

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient is being developed by AMAG Pharmaceuticals for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient receives FDA approval, AMAG Pharmaceuticals (AMAG) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for AMAG on DilutionWatch at dilutionwatch.com/stock/AMAG.html.

You can view the full BiotechSigns company profile for AMAG Pharmaceuticals (AMAG) at biotechsign.com/app/company/AMAG, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.